What is the side effect of plx4032?
Table 1 presents adverse reactions reported in at least 10% of unresectable or metastatic melanoma patients treated with ZELBORAF….Erdheim-Chester Disease (ECD)
Trial 4: Patients with ECD | ||
---|---|---|
Body System Adverse Reactions | n=22 | |
Diarrhea | 50 | – |
Nausea | 32 | – |
Vomiting | 23 | – |
What are the side effects of Trametinib?
More common
- Burning, itching, and pain in hairy areas, pus at the root of the hair.
- canker sores.
- change in taste.
- dry eyes.
- dry skin.
- itching, pain, redness, swelling, tenderness, or warmth on the skin.
- loosening of the fingernails.
- loss of taste.
What is Cotellic used for?
COTELLIC is a prescription medicine that is used with the medicine ZELBORAF, to treat a type of skin cancer called melanoma that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene.
How much does Cobimetinib cost?
The cost for Cotellic oral tablet 20 mg is around $7,323 for a supply of 63 tablets, depending on the pharmacy you visit.
What does PLX4032 mean?
Vemurafenib (PLX4032, RG7204, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-RafV600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy. Nature, 2014, 3;508 (7494):118-22.
How does PLX4032 work in melanoma?
“PLX4032, a Selective BRAF (V600E) Kinase Inhibitor, Activates the ERK Pathway and Enhances Cell Migration and Proliferation of BRAF (WT) Melanoma Cells”. Pigment Cell Melanoma Res. 23 (2): 190–200. doi: 10.1111/j.1755-148X.2010.00685.x.
How does PLX4032 work in BRAF cells?
PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF. Thus, PLX4032 inhibits ERK signaling output in a mutant BRAF-selective manner.
What is the difference between PLX4032 and MEK inhibitors?
In BRAF(V600E) tumor cells, MEK and RAF inhibitors affect the expression of a common set of genes. PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF.